HARVARD BIOSCIENCE INC Cash Flow Statement
HBIO|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
$1M
FY2025
Free Cash Flow
-$1M
FY2025
Capital Expenditures
$3M
Cash used for long-term assets
Dividends Paid
N/A
FY2025
HARVARD BIOSCIENCE INC generated $1M in operating cash flow and negative free cash flow of $1M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$12.4M | -$3.4M | -$9.5M | -$288.0K | -$7.8M | -$4.7M | -$2.9M | -$865.0K | -$19.0M | $2.4M | -$1.8M | $2.4M | $3.8M | $19.0M | $7.2M |
| Depreciation & Amortization | $1.7M | $1.5M | $1.5M | $1.8M | $1.9M | $2.0M | $2.4M | $1.3M | $1.7M | $1.3M | $1.3M | $1.3M | $1.3M | $3.9M | $1.2M |
| Operating Cash Flow | $1.4M | $14.0M | $1.2M | $1.3M | $9.3M | $8.0M | $2.9M | $1.1M | $705.0K | $4.4M | $4.1M | $8.1M | $6.6M | $12.3M | $16.5M |
| Capital Expenditures | $2.6M | $1.8M | $1.6M | $1.2M | $1.2M | $1.2M | $986.0K | $890.0K | - | - | - | - | - | - | - |
| Free Cash Flow | -$1.2M | $12.2M | -$438.0K | $67.0K | $8.2M | $6.8M | $1.9M | $167.0K | - | - | - | - | - | - | - |
| FCF Margin | -1.3% | 10.9% | -0.4% | 0.1% | 8.0% | 5.9% | 1.6% | 0.2% | - | - | - | - | - | - | - |